What is fluticasone propionate 50 µg?

What is Fluticasone Propionate 50 mcg?

Fluticasone propionate 50 mcg is an inhaled corticosteroid (ICS) formulation used primarily for the treatment of asthma and allergic rhinitis, representing one of the lowest available doses of this potent synthetic corticosteroid.

Medication Overview

Fluticasone propionate is a synthetic trifluorinated corticosteroid with high glucocorticoid receptor affinity and potent topical anti-inflammatory activity 1. The 50 mcg dose refers to the amount delivered per actuation or inhalation, depending on the formulation.

Available Formulations

The 50 mcg strength is available in multiple delivery systems:

• Nasal spray: 50 mcg per spray for allergic rhinitis 2
• Dry powder inhaler (DPI): 50 mcg per inhalation for asthma 1
• Metered-dose inhaler (MDI): Various formulations delivering approximately 50 mcg per puff

Clinical Applications

For Asthma

In children and adults with persistent asthma, fluticasone propionate 50 mcg twice daily (100 mcg/day total) represents an effective low-dose ICS regimen 3, 4. This dosage:

• Produces significant improvements in lung function (FEV1 and peak expiratory flow) compared to placebo 3, 5, 4
• Reduces asthma symptoms, nighttime awakenings, and rescue medication use 3, 5
• Can maintain asthma control in patients previously stabilized on higher doses 6

In pediatric studies, 50 mcg twice daily demonstrated superiority over placebo with mean increases in morning peak expiratory flow of 22 L/min at week 1 and 50 L/min at endpoint 3. The therapeutic effect begins within the first week of treatment 3, 5.

For Allergic Rhinitis

For allergic rhinitis, fluticasone propionate 50 mcg per spray (typically 1-2 sprays per nostril daily) is FDA-approved for patients aged 4 years and older 2. Intranasal corticosteroids are the most effective medication class for controlling allergic rhinitis symptoms 7.

The nasal formulation:

• Provides relief of sneezing, nasal congestion, discharge, and itching 7
• Has onset of therapeutic effect between 3-12 hours 7
• Is more effective than oral antihistamines and leukotriene antagonists 8, 7

Off-Label Use: Eosinophilic Esophagitis

Fluticasone propionate 220-440 mcg twice daily (swallowed, not inhaled) has been used off-label for eosinophilic esophagitis in pediatric patients, with clinical and histologic improvement in 31 of 33 patients studied 9. The medication is sprayed into the mouth with lips sealed around the device, then swallowed without rinsing, with no eating or drinking for 30 minutes afterward 9.

Pharmacology

Mechanism of Action

Fluticasone propionate exerts anti-inflammatory effects through:

• High glucocorticoid receptor binding affinity
• Local action in target tissues (lung, nasal mucosa)
• Minimal systemic bioavailability (<1% oral absorption) due to extensive first-pass metabolism 1

Absorption and Bioavailability

• Peak plasma concentrations occur 1-2 hours after inhalation 1
• Absolute bioavailability is approximately 5.3-5.5% for inhaled formulations 1
• The majority of systemically absorbed drug comes from lung deposition, not swallowed portions 1

Safety Profile

Local Side Effects

Common local adverse effects include:

• Oral candidiasis (≤8% incidence at doses ≤250 mcg twice daily) 10
• Nasal irritation or epistaxis (nasal formulations) 2, 7
• Pharyngitis 2
• Dysphonia (inhaled formulations)

Systemic Effects

At the 50 mcg dose, systemic effects are minimal 7, 10:

• HPA axis suppression: No clinically significant effects demonstrated at recommended doses 7
• Growth in children: Studies with fluticasone propionate at recommended doses show no effect on growth 7
• Bone density: No consistent effects on bone density at doses ≤500 mcg/day 7
• Ocular effects: No significant effects on intraocular pressure or cataract formation 7

A meta-analysis found that fluticasone might lead to bone loss at total daily doses higher than 750 mcg/day, but this risk is substantially lower with the 50 mcg twice daily regimen 9.

Dosing Considerations

Asthma Dosing

• Children (4-11 years): 50-100 mcg twice daily 11
• Adolescents and adults: 50-250 mcg twice daily, depending on severity 11, 10
• Maintenance after stabilization: 50 mcg twice daily can maintain control in patients previously requiring higher doses 6

Allergic Rhinitis Dosing

• Children (4-11 years): 1 spray (50 mcg) per nostril daily 2
• Adults: 2 sprays (100 mcg) per nostril daily, may reduce to 1 spray per nostril for maintenance 2

Comparative Efficacy

Fluticasone propionate is approximately twice as potent as beclomethasone dipropionate, budesonide, or flunisolide on a microgram-per-microgram basis 10. This means 50 mcg of fluticasone propionate is roughly equivalent to 100 mcg of these other inhaled corticosteroids 12, 10.

When compared to other medications:

• More effective than nedocromil, theophylline, or zafirlukast 10
• More effective than oral antihistamines for allergic rhinitis 7
• Equivalent or superior to other ICS at half the dose 10

Important Clinical Pearls

• Proper administration technique is critical: For nasal sprays, avoid spraying directly at the nasal septum to minimize epistaxis risk 7
• Onset of action: Therapeutic effects begin within 3-12 hours for most patients, with maximal benefit at 1-2 weeks 7
• Dose titration: Once asthma control is achieved, titrate to the minimum effective dose 11
• Combination therapy: In moderate-to-severe asthma, adding a long-acting beta-agonist to low-dose fluticasone (100-250 mcg/day) is preferred over increasing the ICS dose 12